Pharmaceutical companies, however, are fairly guarded – even wary – in their approach to social media, mainly because of the various regulations governing the industry. While companies in other industries freely participate in the conversations - responding to questions, correcting misinformation and providing a clarification wherever required – most pharmaceutical companies are hesitant to do so.
In this white paper, we evaluate the case for pharmaceutical companies to monitor conversations on social media and to explore the possible options in this regard.